AG825

AG825 (also known as Tyrphostin AG 825) is a selective, ATP-competitive inhibitor of the tyrosine kinase activity of HER2/Neu (ErbB2). Developed by researchers at the Hebrew University of Jerusalem, AG825 inhibits HER2 autophosphorylation with an IC50 of 0.35 µM in cell-free assays, demonstrating high selectivity over EGFR (ErbB1) and PDGFR. It is widely utilized as a research-use-only laboratory tool to investigate HER2-mediated signaling pathways, cell cycle regulation, and apoptosis in various oncology models, including breast and prostate cancers, as well as its potential anti-inflammatory effects.

Other names

3-[3-[(2-benzothiazolylthio)methyl]-4-hydroxy-5-methoxyphenyl]-2-cyano-2-propenamideTyrphostin AG 825Tyrphostin AG-825Tyrphostin C15